Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Dong Woo Shin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2078-3298; OpenAlex author ID A5101591138. Sources: OpenAlex.

Their work

Papers
12 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2019: 1 paper · 2020: 5 papers · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 12

  1. Chemotherapy for Older Adults with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis. Co-author DOI 10.3390/jcm15062254↗
  2. Development of a serum protein biomarker panel for the diagnosis of pancreatic ductal adenocarcinoma using a machine learning approach. Co-author DOI 10.1038/s41598-025-19631-1↗
  3. Differentiation of autoimmune pancreatitis from pancreatic adenocarcinoma using CT characteristics: a systematic review and meta-analysis. Co-author DOI 10.1007/s00330-023-09959-5↗
  4. Multi-Phase, Contrast-Enhanced Computed Tomography-Based Radiomic Prognostic Marker of Non-Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers14102476↗
  5. Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A bi… Co-author DOI 10.1016/j.pan.2021.02.022↗
  6. Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients. Co-author DOI 10.1186/s13104-021-05681-x↗
  7. Reply to the letter to the editor: 'AJCC 8th edition staging system for pancreatic ductal adenocarcinoma: A controversial step forward?' Co-author DOI 10.1016/j.ejso.2019.10.021↗
  8. Tolerability and safety of EUS-injected adenovirus-mediated double-suicide gene therapy with chemotherapy in locally advanced pancreatic cancer: a phase 1 tria… First author DOI 10.1016/j.gie.2020.02.012↗
  9. Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry. Co-author DOI 10.1097/coc.0000000000000730↗
  10. The American Joint Committee on Cancer 8th edition staging system for the pancreatic ductal adenocarcinoma: is it better than the 7th edition? Co-author DOI 10.21037/hbsn.2019.08.06↗
  11. Primary Granulocyte Colony-Stimulating Factor Prophylaxis in Metastatic Pancreatic Cancer Patients Treated with FOLFIRINOX as the First-Line Treatment. First author DOI 10.3390/cancers12113137↗
  12. Validation of the American Joint Committee on Cancer 8th edition staging system for the pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2019.06.002↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin‐Hyeok Hwang · 9 shared papers, 2019–2025 · strength 1.52
  2. Jong-Chan Lee · 8 shared papers, 2019–2026 · strength 1.34
  3. Jaihwan Kim · 8 shared papers, 2019–2022 · strength 1.19
  4. Sung‐Hoon Moon · 2 shared papers, 2023–2026 · strength 0.58
  5. Yuna Youn · 2 shared papers, 2020–2025 · strength 0.45
  6. Yoo‐Seok Yoon · 2 shared papers, 2019–2021 · strength 0.23
  7. Ho‐Seong Han · 2 shared papers, 2019–2021 · strength 0.23
  8. Moon Hyung Choi · 1 shared paper, 2023 · strength 0.19
  9. Min-Jeong Kim · 1 shared paper, 2023 · strength 0.19
  10. Tae Yeon Jeon · 1 shared paper, 2023 · strength 0.19
  11. Ji Hye Min · 1 shared paper, 2023 · strength 0.19
  12. Sang Min Lee · 1 shared paper, 2023 · strength 0.19
  13. Seung Bae Yoon · 1 shared paper, 2023 · strength 0.19
  14. Young Hoon Kim · 1 shared paper, 2022 · strength 0.19
  15. Woo Jin Lee · 2 shared papers, 2019–2020 · strength 0.18
  16. Sang Myung Woo · 2 shared papers, 2019–2020 · strength 0.18
  17. Haeryoung Kim · 1 shared paper, 2021 · strength 0.15
  18. Jae Hyup Jung · 1 shared paper, 2020 · strength 0.15
  19. Jae Hyeong Kim · 1 shared paper, 2020 · strength 0.12
  20. Jin Won Kim · 1 shared paper, 2020 · strength 0.10
  21. Jinkook Kim · 1 shared paper, 2020 · strength 0.10
  22. Eun Kyung Hong · 1 shared paper, 2019 · strength 0.08
  23. Sung‐Sik Han · 1 shared paper, 2019 · strength 0.08
  24. Sang‐Jae Park · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.